Informed Design of Bioanalytical PCR Assay Testing Parameters
PPD
OCTOBER 12, 2023
These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025.
52 
Let's personalize your content